• Je něco špatně v tomto záznamu ?

Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient-Physician Perspective

G. Saglio, G. Sharf, A. Almeida, A. Bogdanovic, F. Bombaci, J. Čugurović, N. Deekes, V. Garcia-Gutiérrez, J. de Jong, Š. Narbutas, P. Westerweel, D. Zackova,

. 2018 ; 18 (6) : 375-379. [pub] 20180425

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035251

Treatment-free remission (TFR) after discontinuation of tyrosine kinase inhibitor therapy is now an emerging treatment goal for patients with chronic myeloid leukemia, who have achieved a deep and stable response to treatment. Although guidance is now available, patients' questions regarding this progressive concept have yet to be addressed. The overall aim of this European Steering Group is a patient-centered approach that educates patients on their treatment options, including TFR, facilitates better patient-physician relationships, and meets patients' emotional and psychological needs. The present report outlines 5 key topic areas on discontinuing tyrosine kinase therapy and the implications of TFR for patient-physician consideration: what TFR is; when TFR is appropriate; which patients might and might not be eligible for TFR; and patients' considerations for discontinuing therapy, such as tyrosine kinase withdrawal syndrome, potential psychological implications, molecular recurrence, and repeat treatment. This Steering Group advocates that patients with chronic myeloid leukemia should have access to high-quality, frequent molecular monitoring and be treated in a specialist center with appropriate medical and psychological support. As patient concerns with attempting TFR become forefront in patient-physician discussions, a greater number of eligible patients might be willing to discontinue therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035251
003      
CZ-PrNML
005      
20191014094142.0
007      
ta
008      
191007s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clml.2018.04.005 $2 doi
035    __
$a (PubMed)29753691
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Saglio, Giuseppe $u Department of Clinical and Biological Sciences, University of Turin, Turin, Italy. Electronic address: gsaglio@unito.it.
245    10
$a Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient-Physician Perspective / $c G. Saglio, G. Sharf, A. Almeida, A. Bogdanovic, F. Bombaci, J. Čugurović, N. Deekes, V. Garcia-Gutiérrez, J. de Jong, Š. Narbutas, P. Westerweel, D. Zackova,
520    9_
$a Treatment-free remission (TFR) after discontinuation of tyrosine kinase inhibitor therapy is now an emerging treatment goal for patients with chronic myeloid leukemia, who have achieved a deep and stable response to treatment. Although guidance is now available, patients' questions regarding this progressive concept have yet to be addressed. The overall aim of this European Steering Group is a patient-centered approach that educates patients on their treatment options, including TFR, facilitates better patient-physician relationships, and meets patients' emotional and psychological needs. The present report outlines 5 key topic areas on discontinuing tyrosine kinase therapy and the implications of TFR for patient-physician consideration: what TFR is; when TFR is appropriate; which patients might and might not be eligible for TFR; and patients' considerations for discontinuing therapy, such as tyrosine kinase withdrawal syndrome, potential psychological implications, molecular recurrence, and repeat treatment. This Steering Group advocates that patients with chronic myeloid leukemia should have access to high-quality, frequent molecular monitoring and be treated in a specialist center with appropriate medical and psychological support. As patient concerns with attempting TFR become forefront in patient-physician discussions, a greater number of eligible patients might be willing to discontinue therapy.
650    _2
$a rozhodování $7 D003657
650    _2
$a lidé $7 D006801
650    _2
$a chronická myeloidní leukemie $x farmakoterapie $x mortalita $7 D015464
650    _2
$a lokální recidiva nádoru $x prevence a kontrola $7 D009364
650    _2
$a vzdělávání pacientů jako téma $7 D010353
650    12
$a vztahy mezi lékařem a pacientem $7 D010817
650    _2
$a inhibitory proteinkinas $x farmakologie $x terapeutické užití $7 D047428
650    _2
$a tyrosinkinasy $x antagonisté a inhibitory $7 D011505
650    _2
$a kvalita života $7 D011788
650    _2
$a indukce remise $x metody $7 D012074
650    _2
$a míra přežití $7 D015996
650    _2
$a výsledek terapie $7 D016896
650    12
$a nenasazení léčby $7 D028761
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Sharf, Giora $u CML Advocates Network, Netanya, Israel.
700    1_
$a Almeida, Antonio $u Hospital da Luz, Lisbon, Portugal.
700    1_
$a Bogdanovic, Andrija $u Clinical Centre of Serbia, University of Belgrade, School of Medicine, Belgrade, Serbia.
700    1_
$a Bombaci, Felice $u Gruppo AIL Pazienti Leucemia Mieloide Cronica, Rome, Italy.
700    1_
$a Čugurović, Jelena $u CML Association of Serbia, Belgrade, Serbia.
700    1_
$a Deekes, Nigel $u CML UK, Birmingham, United Kingdom.
700    1_
$a Garcia-Gutiérrez, Valentín $u Hospital Universitario Ramón y Cajal, Ramón y Cajal Health Research Institute, Madrid, Spain.
700    1_
$a de Jong, Jan $u Hematon Foundation, Utrecht, The Netherlands.
700    1_
$a Narbutas, Šarūnas $u POLA, Lithuanian Cancer Patient Coalition, Kaunas, Lithuania.
700    1_
$a Westerweel, Peter $u Albert Schweitzer Hospital, Dordrecht, The Netherlands.
700    1_
$a Zackova, Daniela $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
773    0_
$w MED00180199 $t Clinical lymphoma, myeloma & leukemia $x 2152-2669 $g Roč. 18, č. 6 (2018), s. 375-379
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29753691 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191014094606 $b ABA008
999    __
$a ok $b bmc $g 1451911 $s 1073801
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 18 $c 6 $d 375-379 $e 20180425 $i 2152-2669 $m Clinical lymphoma, myeloma & leukemia $n Clin Lymphoma Myeloma Leuk $x MED00180199
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Možnosti archivace